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Abstract
Background: ARTS-II was designed to evaluate the sirolimus-eluting stent (SES) versus ARTS-I. The objec-
tive of this analysis is to assess the safety and efficacy of the SES in diabetic patients with multivessel dis-
ease (MVD) versus both arms of ARTS-I.
Methods and results: The ARTS studies included 367 diabetic patients (ARTS-II: 159; ARTS-I-CABG: 96;
ARTS-I-PCI: 112). Baseline characteristics showed a more diseased patient population in the ARTS-II
study: 50.3% with 3VD vs. 35.4% (ARTS-I-CABG) and 30.8% (ARTS-I-PCI) (p=0.003). Treated or anasto-
mosed lesions were 3.2±1.2 (ARTS-II), 2.8±0.8 (ARTS-I-CABG) and 2.5±1.1 (ARTS-I-PCI). At 30 days
there was a significant difference in MACCE between ARTS-II (4.4%) and ARTS-I-PCI (12.5%) (p=0.02).
At 1-year, the death rate was 2.5% (ARTS-II) vs. 3.1% (ARTS-I-CABG) and 6.3% (ARTS-I-PCI) without sig-
nificant differences. Myocardial infarction rate was 0.6% (ARTS-II) vs. 2.1% (ARTS-I-CABG; p=0.56) and
6.3% (ARTS-I-PCI; p=0.01). The need for repeat revascularization was 12.6% (ARTS-II) vs. 4.2% (ARTS-
I-CABG; p=0.027) and 22.3% (ARTS-I-PCI; p= 0.046). MACCE-free survival was 84.3% (ARTS-II) vs.
85.4% (ARTS-I-CABG; p=0.86) and 63.4% (ARTS-I-PCI; p<0.001). Also at 1 year, the overall MACCE rate
in patients with diabetes was significantly higher than in nondiabetic patients, 15.7% vs. 8.5%, respectively
[RR 1.85, 95%CI (1.16,2.97), p=0.015), due to a higher incidence of death and need for repeat revascu-
larization, 2.5% vs. 0.4 and 12.5% vs. 5.6% in diabetes vs. nondiabetes groups, respectively.
Conclusion: Despite more extensive and treated disease, the overall MACCE-free survival in diabetic patients
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Multivessel revascularization in diabetic patients
Introduction
Patients with diabetes mellitus have a greater incidence of athero-
sclerotic disease associated with a worse prognosis. The absolute
risk of cardiac death is three times higher compared to nondiabetic
patients1,2. In addition, diabetic patients undergoing coronary artery
revascularization, have a worse outcome than nondiabetic patients3.
Subgroup analysis of the Bypass Angioplasty Revascularization
Investigation (BARI)4 and Emory Angioplasty versus Surgery Trial
(EAST)5, both randomized studies, demonstrated that diabetic
patients with multivessel coronary disease (MVD) had worse long-
term outcome when treated with balloon angioplasty than with
CABG. Specifically, in the BARI study patients receiving at least one
internal mammary artery graft had less cardiac mortality (5.8% ver-
sus 20.6%, P=.0003), than patients treated with balloon angioplasty.
In the bare-metal stent era, multiple stenting in diabetic patients
resulted in a higher incidence of in-hospital CABG, a higher need for
repeat revascularization during follow-up and a lower one-year sur-
vival rate than in nondiabetic patients6. The Arterial Revascularization
Therapy Study (ARTS-I) compared multivessel coronary artery stent-
ing with CABG surgery7. In the subgroup of diabetic patients there
was no statistically significant difference in mortality at 1 and at
3 years between the 2 groups8; however diabetic patients who under-
went PCI required more repeat revascularization procedures8.
Moreover at 5 years9, in patients with diabetes, those who underwent
stenting had a mortality rate of 13.4%, versus 8.3% in those who
underwent CABG (p = 0.27; RR, 1.61; 95% CI, 0.71 to 3.63). Within
the stent group, diabetic patients had a significantly higher mortality
rate than non-diabetic patients (13.4% vs. 6.8%; p = 0.03; RR, 1.98;
95% CI, 1.11 to 3.52). There was no significant mortality difference
between the diabetic and non-diabetic patients within the CABG
group (8.3% vs. 7.5%; p =0.8; RR, 1.12; 95% CI, 0.54 to 2.32).
Diabetic patients treated with bare-metal stent also had a lower
event-free survival at five years than non-diabetic patients. The
MACCE rate at five years in diabetic patients treated with stents was
54.5%, versus 38.7% in non-diabetics (p = 0.003). Conversely,
there was no significant difference in the five-year MACCE rate
between diabetic and non-diabetic patients treated with CABG
(25.0% vs. 21.2%, p = 0.42). The difference in MACCE rate
between diabetic and non-diabetic patients treated with stenting is
predominantly attributable to the higher rate of repeat revasculariza-
tion in diabetic patients (42.9% vs. 27.5%, p=0.002).
Sirolimus-eluting stents (SES) have been shown to significantly
reduce restenosis and, consequently reduce the need for repeat
coronary revascularization in randomized trials10-12. The potential of
SES for the treatment of multivessel disease in diabetics is
unknown. The Arterial Revascularization Therapy Study II (ARTS-II)
was designed to evaluate the SES versus ARTS-I13,14. The objective
of this analysis is to assess the safety and efficacy of the SES in dia-
betic patients with MVD versus both arms of ARTS-I.
Methods
ARTS-II STUDY DESIGN
This multicentre, non-randomized, stratified, non-inferiority study
was designed to evaluate sirolimus-eluting stent (SES) implantation
in patients with multivessel disease using the surgical group of
ARTS-I as an historical control. ARTS-I enrolled patients between
April 1997 and June 1998. Both studies ARTS-I and ARTS-II used
the same inclusion/exclusion criteria.13
Patients with stable or unstable angina, or silent ischemia were
enrolled. The left anterior descending (LAD) artery and at least
another significant lesion (>50% diameter stenosis) in a different
major epicardial coronary artery had to be treated. Stents with a
diameter of 2.5 to 3.5 mm and length up to 33 mm were used.
Patients with any prior coronary intervention, left main coronary
disease, overt congestive heart failure or a left ventricular ejection
fraction of less than 30% were excluded. Additional exclusion cri-
teria included: history of a cerebrovascular accident, transmural
myocardial infarction in the preceding week, severe hepatic or
renal disease, neutropenia or thrombocytopenia, intolerance or
contraindication to acetylsalicylic acid or thienopyridines, need for
concomitant major surgery, and life-limiting major non-cardiac dis-
eases. The study was approved by the ethical committees of each
participation institution. All patients signed informed consent prior
to study entry.
Study population
All patients enrolled in the ARTS-I trial and ARTS-II were included
in the present analysis. Patients were divided into 2 groups: dia-
betes (367) and non-diabetes (1445).
Study objectives
The primary objective of this analysis is to evaluate the diabetic
patients in ARTS-II to both arms of ARTS-I with respect to MACCE
at 1-year; the secondary objective is to assess 1-year outcomes
between diabetic and nondiabetic in ARTS-II.
End point definitions
Death from all causes were reported, and categorised as cardiac
unless there was documentation to the contrary. Cerebrovascular
events (CVA) included: stroke, transient ischaemic attacks, and
reversible ischaemic neurologic deficits. Within 7 days after the
intervention, a diagnosis of myocardial infarction was made if new
abnormal Q-waves (according to the Minnesota code) and either
a ratio of serum creatine kinase MB (CK-MB) isoenzyme to total
cardiac enzyme that was greater than 0.1 or a CK-MB value that
was 5 times the upper limit of normal were present. Serum crea-
tine kinase levels were measured 6 and 12 hours after the inter-
vention and before discharge. Beginning 8 days after the interven-
tion, either abnormal Q-waves or enzymatic changes were suffi-
cient for a diagnosis of myocardial infarction. This two-part
method of defining myocardial infarction was developed for ARTS-I
to address the difficulty of diagnosing a myocardial infarction after
surgery. A myocardial infarction was confirmed only after the rel-
evant electrocardiograms had been analysed by the electrocardio-
graphic core laboratory and adjudicated by an independent clini-
cal event committee. All repeat revascularization procedures were
recorded. Events were counted from the time of the start of the ini-
tial procedure.
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Statistical analysis
Demographic and procedural characteristics of diabetic patients
were compared between ARTS-II and ARTS-I (CABG and PCI).
Similar comparison was performed for nondiabetic patients.
Continuous variables are expressed as mean±standard deviation.
Categorical variables are presented as percentages. The F-test from
an analysis of variance for continuous variables and the Fisher’s
exact test for categorical variables were used.
A separate multivariate regression analysis was performed to deter-
mine independent predictors of MACCE within the ARTS-II popula-
tion only. Clinically important baseline and procedural characteris-
tics were tested on a per patient basis by univariate analysis to
determine suitability for inclusion in the multivariate model. These
variables were then entered into a stepwise logistic regression
model with entry and stay criteria of 0.20 and 0.05 respectively.
MACCE at 30 days and 1 year are presented as counts and percent-
ages and were compared in terms of relative risks (ARTS-II vs. both
ARTS-I arms) with 95% confidence intervals. Time-to-event vari-
ables are presented as Kaplan-Meier curves, and the overall inci-
dence was tested using the log-rank test. An adjustment for the dif-
ferences in the baseline characteristics between ARTS-I and ARTS-
II populations was performed by univariate frailty analysis on the
MACCE, using a Weibull distribution. The covariates in the model,
which considered ARTS-I-CABG and ARTS-II populations, were
age, hypercholesterolemia, hypertension, previous MI, family histo-
ry of MI, no. of lesions type B2/C and three vessel disease. In the
model, that compared the differences with ARTS-I-PCI, the same
variables were included plus maximum inflation pressure and total
stented length.
Results
Between February 2003 and November 2003, 607 patients, of
whom 159 diabetic patients, were treated at 45 participating cen-
tres in the ARTS-II study. Table 1 and 2 present the baseline demo-
graphic and angiographic characteristics of the 3 treatment groups
in diabetic and nondiabetic patients.
Baseline characteristics
DIABETIC PATIENTS IN ARTS-I AND ARTS-II
ARTS-II had a significantly higher percentage of patients with hyper-
tension: 79.9% (ARTS-II) vs. 56.3% (ARTS-I-CABG) and 64.3%
(ARTS-I-PCI), p <0.0001. Also hypercholesterolemia increased
from 49.0% (ARTS-I-CABG) and 55.4% (ARTS-I-PCI) to 74.1% in
the ARTS-II study, p <0.0001. Among the diabetic patients, 28
(17.6%) (ARTS-II), 16 (16.7%) (ARTS-I-CABG) and 23 (20.5%)
(ARTS-I-PCI) required insulin treatment. The percentage of three
vessel disease was 50.3% in ARTS-II vs. 35.4% in ARTS-I-CABG
and 30.8% in ARTS-I-PCI, p=0.003. The mean number of signifi-
Clinical research
Table 1. Baseline Patient Demographics and Clinical Characteristics
Diabetic patients Non-diabetic
ARTS-II ARTS-I-PCI ARTS-I-CABG P-value ARTS-II ARTS-I-PCI ARTS-I-CABG P-value
(N=159 (N=112 (N=96 (N=448 (N=488 (N=509 
patients) patients) patients) patients) patients) patients)
Age (yrs) 64.5±8.7 62.5±9.1 62.6±9.2 0.12 62.2±9.9 60.2±9.7 61.0±9.4 0.006
Ejection Fraction (%) 59.5±11.8 60.5±12.5 60.3±13.7 0.81 60.4±11.5 61.0±12.2 60.4±13.2 0.65
Body Mass Index (kg/m2) 28.8±4.5 28.7±3.7 28.1±3.8 0.38 27.1±3.8 26.9±3.6 27.2±3.6 0.30
Male % 66.7 73.2 68.8 0.53 80.1 77.9 77.4 0.56
Diabetes insulin-treated % 4.6 3.8 2.6 0.78
Hypertension % 79.9 64.3 56.3 <0.0001 62.7 40.2 42.8 <0.0001
Hypercholesterolemia % 74.1 55.4 49.0 <0.0001 73.8 58.6 59.3 <0.0001
History of CVA (ARTS-II) or TIA (ARTS-I) % 1.3 0.0 0.0 0.5 0.7 1.0 1.2 0.75
Family history of MI/sudden death <55 yr % 33.8 41.4 32.6 0.34 36.7 38.6 43.7 0.07
Peripheral Vascular Disease % 8.2 5.4 7.3 0.7 6.5 5.5 4.7 0.5
Previous MI % 29.6 41.1 49.0 0.006 36.2 45.1 40.7 0.02
Previous PTCA % 0.0 1.8 2.1 0.17 0.7 1.4 2.4 0.11
Carotid Surgery % 1.9 0.0 1.0 0.38 1.1 0.6 1.0 0.74
Chronic Obstructive Pulmonary Disease % 3.2 4.5 3.1 0.82 3.8 5.1 5.1 0.52
Smoking History %
– Previous 36.5 42.0 46.9 0.25 42.4 44.2 46.6 0.43
– Current 11.9 20.5 16.7 0.15 21.9 29.6 27.5 0.2
Unstable Angina % 32.1 37.5 33.3 0.64 37.9 37.7 37.9 0.99
Stable Angina % 53.5 58.9 62.5 0.35 53.1 55.7 57.2 0.45
Silent Ischaemia % 14.5 3.6 4.2 0.002 8.9 6.6 4.9 0.05
CVA: CerebroVascular Accident; TIA=Transient Ischaemic Attack; MI: Myocardial Infarction; CABG: Coronary Artery Bypass Graft;
PTCA: Percutaneous Transluminal Coronary Angioplasty
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cant lesions per patient was 3.2±1.2 in ARTS-II versus 2.5±1.1 in
ARTS-I-PCI, p <0.0001. ARTS-II patients received 3.6±1.5 stents
with an average total stent length of 73.9±31.9 mm vs. 3.0±1.5 and
52.7±25.6 mm in ARTS-I-PCI, both with p=0.002 and p <0.0001,
respectively.
The mean duration of the procedure was 83 minutes in ARTS-II ver-
sus 201 minutes in ARTS-I-CABG and 104 minutes in ARTS-I-PCI
(Table 2). Post-procedurally, patients were hospitalized for
3.6±2.9 days after ARTS-II versus 11.0±7.3 days after ARTS-I-
CABG and 4.6±3.4 days in ARTS-I-PCI.
DIABETIC VERSUS NON-DIABETIC PATIENTS IN ARTS-II
There were fewer male patients in the diabetic subgroup. Diabetic
patients had a significantly higher percentage of hypertension and
silent ischaemia. The use of glycoprotein IIb/IIIa inhibitors was sim-
ilar between the two subgroups.
Short-term clinical outcome in diabetic patients
Up to 30 days, ARTS-II diabetics had a similar incidence of MACCE
compared to ARTS-I-CABG (4.4% vs. 7.3%, p=0.40) and a lower
incidence compared to ARTS-I-PCI (12.5%, p=0.02). Three CVAs
were reported, all occurring in the ARTS-I-CABG arm. (Table 3)
There were 2 angiographically documented sub-acute thromboses
in ARTS-II (1.3%) and 2 in the ARTS-I-PCI (1.8%). All events
occurred before the patients were discharged.
One-year clinical outcome in diabetic patients
Patients showed a similar incidence of MACCE in ARTS-II and ARTS-
I-CABG (Table 4) (Figure 1). However, patients assigned to ARTS-I-
CABG had a higher incidence of cerebrovascular events than
patients in ARTS-II, 0% vs. 5.2% respectively, p=0.007. Conversely,
the need for repeat revascularization was higher in ARTS-II that in
ARTS-I-CABG, 12.6% vs. 4.2%, respectively [RR 3.02, 95%CI
Table 2. Angiographic and procedure characteristics
Diabetic patients Non-diabetic
ARTS-II ARTS-I-PCI ARTS-I-CABG P-value ARTS-II ARTS-I-PCI ARTS-I-CABG P-value
(N=159 (N=112 (N=96 (N=448 (N=488 (N=509 
patients) patients) patients) patients) patients) patients)
Location of lesion %
– RCA 28.5 30.4 29.0 0.83 29.3 31.3 29.6 0.46
– LM 0.0 0.0 0.0 0.0 0.1 0.1 0.53
– LAD 40.7 36.6 40.7 0.45 41.8 40.1 41.2 0.64
– LCX 30.8 33.0 30.3 0.74 28.9 28.5 29.2 0.94
Lesion classification %
– Type A/B1 27.0 29.8 36.2 0.021 31.4 32.9 38.6 <0.0001
– Type B2/C 73.0 70.2 63.8 0.021 68.6 67.1 61.4 <0.0001
Number of diseased arteries %
– Single 0.6 3.7 1.0 0.15 0.2 4.0 4.2 <0.0001
– Double 49.1 65.4 63.5 0.013 45.1 69.3 66.7 <0.0001
– Triple 50.3 30.8 35.4 0.003 54.7 26.7 29.0 <0.0001
Number of stented lesions 3.2±1.2 2.5±1.1 <0.0001 3.2±1.1 2.5±0.9 <0.0001
Number of stents implanted 3.6±1.5 3.0±1.5 0.002 3.7±1.5 2.7±1.2 <0.0001
Total stent length (mm) 73.9±31.9 52.7±25.6 <0.0001 72.0±32.1 46.4±20.6 <0.0001
Maximum dilatation pressure (Atm) 16.2±2.7 14.9±2.9 <0.0001 16.4±2.9 14.6±2.8 <0.0001
IIB/IIIA inhibitors % 34.0 31.9
Conduit arterial % 93.5 93.2%
Number of anastomoses 2.8±0.8 2.9±1.0
Duration of procedure (minutes) 82.8±39.8 104.0±51.3 200.8±63.5 <0.0001 85.9±44.4 97.5±49.7 191.8±67.2 <0.0001
Days to procedure since randomization 0.1±1.9 10.0±16.8 25.2±29.5 <0.0001 0.1±0.5 10.9±16.4 27.2±40.0 <0.0001
Days in hospital since procedure 3.6±2.9 4.6±3.4 11.0±7.3 <0.0001 3.3±2.6 3.8±3.7 9.4±4.3 <0.0001
Hospital Stay (days) 5.6±4.3 6.2±4.1 14.2±9.2 <0.0001 5.1±4.2 5.5±4.7 12.2±5.7 <0.0001
Figure 1. Kaplan-Meier curves out to 1 year in diabetic patients in
ARTS-I and ARTS-II population. CABG, coronary artery bypass graft;
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(1.06,8.57), p=0.027]. As expected, ARTS-II patients had a lower
incidence of MACCE than patients in ARTS-I-PCI group, 15.7% vs.
36.6% respectively [RR 0.43, 95% CI (0.28,0.66), p<0.001], main-
ly due to the decreased need for repeat revascularization, 12.6% in
ARTS-II vs. 22.3% in ARTS-I-PCI respectively, [RR 0.56, 95%CI
(0.33,0.95), p=0.046]. There was also lower incidence of myocardial
infarction in ARTS-II than in ARTS-I-PCI, 0.6 vs. 6.3% respectively
[RR 0.10, 95%CI (0.01,0.81), p=0.010). One late thrombosis was
recorded in an insulin-treated diabetic patient in ARTS-II.
One-year clinical outcome in ARTS-II 
(diabetes vs. nondiabetes)
The overall MACCE rate in patients with diabetes was significantly
higher than in nondiabetic patients, 15.7% vs. 8.5%, respectively
[RR 1.85, 95%CI (1.16,2.97), p=0.015), due to a higher incidence
of death and need for repeat revascularization, 2.5% vs. 0.4 and
12.5% vs. 5.6% in diabetes vs. nondiabetes groups, respectively.
(Table 5 and Figure 2).
Clinical research
Table 3. MACCE hierarchical - up to 30 days in diabetic patients
ARTS-II ARTS-I-CABG ARTS-II-CABG P-value ARTS-I-PCI ARTS-II-PCI P-value
(N=159 (N=96 Relative risk (N=112 Relative risk 
patients) patients) [95% CI] patients) [95% CI]
MACCE (Death, CVA, MI, CABG, RPTCA) % 4.4 7.3 0.60 [0.22, 1.67] 0.40 12.5 0.35 [0.15, 0.84] 0.020
Death % 0.0 1.0 0.38 4.5 0.011
CVA % 0.0 3.1 0.052 0.0
MI without Death or CVA % 0.6 2.1 0.30 [0.03, 3.28] 0.56 2.7 0.23 [0.02, 2.23] 0.31
– Q-wave MI 0.6 2.1 0.30 [0.03, 3.28] 0.56 2.7 0.23 [0.02, 2.23] 0.31
– Non Q-wave MI 0.0 0.0 0.0
Revascularization without Death or CVA or MI % 3.8 1.0 3.62 [0.44, 29.64] 0.26 5.4 0.70 [0.23, 2.13] 0.56
CABG without Death or CVA or MI % 2.5 1.0 2.42 [0.27, 21.29] 0.65 4.5 0.56 [0.15, 2.05] 0.50
RPTCA without Death or CVA or MI or CABG % 1.3 0.0 0.53 0.9 1.41 [0.13, 15.35] 1.00
MACCE Free % 95.6 92.7 1.03 [0.97, 1.10] 0.40 87.5 1.09 [1.01, 1.18] 0.020
Table 4. MACCE hierarchical - up to 365 days in diabetic patients
ARTS-II ARTS-I-CABG ARTS-II-CABG P-value ARTS-I-PCI ARTS-II-PCI P-value
(N=159 (N=96 Relative risk (N=112 Relative risk 
patients) patients) [95% CI] patients) [95% CI]
MACCE (Death, CVA, MI, CABG, RPTCA) % 15.7 14.6 1.08 [0.59, 1.97] 0.86 36.6 0.43 [0.28, 0.66] <0.001
Death % 2.5 3.1 0.81 [0.18, 3.52] 1.00 6.3 0.40 [0.12, 1.34] 0.21
CVA % 0.0 5.2 0.007 1.8 0.17
MI without Death or CVA % 0.6 2.1 0.30 [0.03, 3.28] 0.56 6.3 0.10 [0.01, 0.81] 0.010
– Q-wave MI 0.6 2.1 0.30 [0.03, 3.28] 0.56 5.4 0.12 [0.01, 0.96] 0.021
– Non Q-wave MI 0.0 0.0 1.00 0.9 0.41
Revascularization without Death or CVA or MI % 12.6 4.2 3.02 [1.06, 8.57] 0.027 22.3 0.56 [0.33, 0.96] 0.046
CABG without Death or CVA or MI % 3.1 1.0 3.02 [0.36, 25.46] 0.41 8.0 0.39 [0.13, 1.14] 0.10
RPTCA without Death or CVA or MI or CABG % 9.4 3.1 3.02 [0.90, 10.16] 0.08 14.3 0.66 [0.34, 1.28] 0.25
MACCE Free % 84.3 85.4 0.99 [0.89, 1.10] 0.86 63.4 1.33 [1.14, 1.55] <0.001
Non-Hierarchical
Death/CVA/MI % 3.1 10.4 0.30 [0.11, 0.86] 0.026 14.3 0.22 [0.08, 0.58] <0.001
Death % 2.5 3.1 0.81 [0.18, 3.52] 1.00 6.3 0.40 [0.12, 1.34] 0.21
CVA % 0 5.2 0.007 1.8 0.17
Myocardial infarction % 0.6 4.2 0.15 [0.02, 1,33] 0.07 8.9 0.07 [0.01, 0.54] 0.001
– Q-wave MI 0.6 4.2 0.15 [0.02, 1,33] 0.07 7.1 0.09 [0.01, 0.69] 0.004
– Non Q-wave MI 0.0 0.0 1.00 1.8 0.17
Revascularization % 13.2 5.2 2.54 [0.99, 6.50] 0.053 28.6 0.46 [0.28, 0.76] 0.003
CABG % 3.1 2.1 1.51 [0.30, 7.63] 0.71 9.8 0.32 [0.11, 0.90] 0.034
RPTCA % 10.1 3.1 3.22 [0.96, 10.76] 0.049 19.6 0.51 [0.28, 0.93] 0.033
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Univariate and multivariate predictors of late
clinical outcome
Independent risk factors for late clinical outcome (MACCE) in the
ARTS-II population are displayed in Table 6 and 7. Diabetes was a
risk factor for the occurrence of MACCE, (Odds Ratio 1.95, p=0.02).
Discussion
The main findings of this analysis are: (1) MACCE-free survival in
diabetic patients at 1 year in ARTS-II is similar to ARTS-I-CABG
(84.3% vs. 85.4%); (2) the MACCE-free survival compared to
ARTS-I-PCI is higher (84.3% vs. 63.4%) primarily driven by a lower
need for revascularization; (3) there was a significantly lower inci-
dence of MACCE at 30 days in ARTS-II than in ARTS-I-PCI; (4) the
presence of diabetes continues to be the most important predictor
of MACCE at 1 year follow up.
Improvement in early outcomes
Despite more extensive and complex coronary artery disease with
more vessels treated in diabetic patients enrolled in ARTS-II, in-hos-
pital clinical outcomes were better than in ARTS-I-PCI patients, and
similar to the ARTS-I-CABG group. The rates of in-hospital MACCE
were 3.1%, 9.8%, and 7.3%, respectively. Interestingly, sub-acute
stent thrombosis (<30 days) in ARTS-II was observed in only 2/159
diabetic patients; whereas one late thrombosis was recorded in an
insulin-treated diabetic patient in ARTS-II despite a high number of
stented lesions (3.2±1.2) and a longer total stented length
(73.9±31.9 mm). The use of glycoprotein IIb/IIIa inhibitors15,16,
compulsive pre-treatment with clopidogrel16,17, a more deliverable
stent and increased operator experience may all have contributed
to this low incidence of early/late adverse events.
Antirestenotic effect of SES
The remarkable antirestenotic effect of the sirolimus-eluting stent
demonstrated in several randomized trials-10-12,19,20, has been
recently confirmed in diabetic patients21,22. The result of the
ARTS-II diabetic subset is in line with these results. In compari-
son with ARTS-I, there was a higher incidence of three-vessel dis-
ease (50%), diffuse lesions, and type C lesions in the ARTS-II
group. Despite this substantially higher risk profile, the need for
repeat revascularization was reduced from 22.3% in ARTS-I-PCI
arm to 12.6% in ARTS-II. Interestingly, but not surprisingly,
ARTS-I-CABG still has the lowest need for revascularization
(4.2%). Indeed, in the ARTS-II study, the presence of diabetes
was the strongest predictor of MACCE events (80% of these were
revascularizations) during follow up.
Figure 2. Kaplan-Meier curves out to 1 year diabetic vs. nondiabetes





























Table 5. MACCE hierarchical - up to 365 days in ARTS-II-Cypher patients
Diabetic patients Nondiabetes patients Relative Risk P-value
(N=159) (N=448) [95% CI]
MACCE (Death, CVA, MI, CABG, RPTCA) % 15.7 8.5 1.85[1.16,2.97] 0.015
Death % 2.5 0.4 5.64[1.04,30.47] 0.043
CVA % 0.0 1.1 0.33
MI without Death or CVA % 0.6 1.3 0.47[0.06,3.87] 0.68
– Q-wave MI 0.6 0.9 0.7[0.08,6.26] 1.0
– Non Q-wave MI 0.0 0.4 1.0
Revascularization without Death or CVA or MI
– CABG without Death or CVA or MI % 3.1 1.6 2.01[0.65,6.25] 0.32
– RPTCA without Death or CVA or MI or CABG % 9.4 4.0 2.35[1.21,4.55] 0.014
MACCE Free % 84.3 91.5 0.92[0.86,0.99] 0.015
Table 6. Univariate Predictors of MACCE at 365 days in ARTS-II 
Coefficient Odds Ratio P-Value
#lesions in left circumflex treated 0.4220 1.50 0.01
#tubular lesions (10-20 mm) 0.3520 1.40 0.01
Diabetes Mellitus 0.6996 2.00 0.01
Number of lesions > 50% DS 0.2089 1.20 0.03
#lesions type B2/C 0.2210 1.20 0.03
Age (years) 0.0303 1.00 0.04
#lesions calcification (moderate/heavy) 0.2137 1.20 0.04
# refers to number.
Table 7. Multivariate Predictors of MACCE at 365 days in ARTS-II
Coefficient Odds Ratio P-Value
Diabetes Mellitus 0.6692 1.95 0.02
#lesions in left circumflex treated 0.4010 1.49 0.01
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Comparison with CABG
Despite the persistent advantage of CABG in terms of a lower need
for revascularization compared to ARTS-II, it is interesting to note
that CABG carried a higher risk for CVA, a finding already reported in
the diabetic subset of ARTS-I23. Overall, at 1 year, the ARTS-II dia-
betic group had a very similar MACCE rate to that seen in the ARTS-
I-CABG group. It is possible that progress in surgical techniques,
such as a greater use of off-pump surgery, may further improve the
surgical results and reduce the risk of cerebral complications.
Comparison with nondiabetics
In ARTS-II, the diabetic patients continued to have a worse outcome
compared to non-diabetics, but the difference was smaller than in
ARTS-I, although still significant.
Diabetes mellitus remains an independent predictor of MACCE at
one year follow up and is associated with a higher incidence of
death and TVR, even with SES usage. Spot treatment provided by
drug-eluting coronary stents on critical lesions cannot prevent the
consequences of further atherosclerosis progression and avoid co-
morbidities associated with this systemic disease.
Limitations
This study is a sub-analysis of the main ARTS-I and ARTS-II trials
– albeit prespecified – and hence suffers from inherent limitations,
such as the lack of sufficient power because of the limited number
of patients in the subgroups to provide definite answers. While the
protocol required that the lesions in ARTS-II be potentially treatable
by CABG, the absence of dialogue with the surgeons prior to the
intervention may have caused a selection bias. Another potential
bias of this study is that a five-year time difference exists between
the groups that were being compared, and technology and medical
practice have improved with time, as have surgical mortality
rates24,25. The study is non-randomized and consequently statistical
adjustment is required to correct for the differences between the
current study population and the historical ARTS-I population.
However, the results of the study after adjustment for differences in
risk factors did not substantially differ from the unadjusted out-
come, since the patients enrolled in ARTS-II were in fact more com-
plex in terms of demographics and lesion characteristics than those
included in ARTS-I. The results of this study pertain only to 1-year
follow-up and the 5-year follow-up of the diabetic patients in ARTS-
I has clearly indicated an increasing difference in outcome between
the surgical and percutaneously treated cohorts of patients.
Whether efficacy of the percutaneous treatment using SES versus
CABG in diabetic patients with multivessel disease will be main-
tained over a longer time period remains to be seen.
Conclusion
When compared to the outcome of the diabetic patients with multi-
vessel disease treated with either PCI or CABG in ARTS-I, the over-
all MACCE-free survival rate at 1 year in ARTS-II is similar to ARTS-
I-CABG and more favourable than ARTS-I-PCI.
Even when treated with drug-eluting stents, diabetes remains an
important predictive risk factor for adverse clinical outcome in
patients with multivessel disease.
Acknowledgement
The co-authors would like to express their gratitude to Brian G. Firth
MD PhD in the drafting of the manuscript.
This study was supported by Cordis, a Johnson & Johnson company.
References
1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality
from coronary heart disease in subjects with type 2 diabetes and in non-
diabetic subjects with and without prior myocardial infarction. N Engl J
Med. 1998;339:229-34.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk
factors, and 12-yr cardiovascular mortality for men screened in the
Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44.
3. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization.
JAMA. 2005;293:1501-8.
4. Influence of diabetes on 5-year mortality and morbidity in a ran-
domized trial comparing CABG and PTCA in patients with multivessel dis-
ease: the Bypass Angioplasty Revascularization Investigation (BARI).
Circulation. 1997;96:1761-9.
5. King SB, 3rd, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS.
Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST).
J Am Coll Cardiol. 2000;35:1116-21.
6. Mehran R, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, Aymong ED,
Fahy M, Moses JW, Stone GW, Leon MB. Short- and long-term results
after multivessel stenting in diabetic patients. J Am Coll Cardiol.
2004;43:1348-54.
7. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ,
Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA,
Morel MA, van Hout BA. Comparison of coronary-artery bypass surgery
and stenting for the treatment of multivessel disease. N Engl J Med.
2001;344:1117-24.
8. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV,
Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B,
Hugenholtz PG, Unger F, Serruys PW. Clinical and economic impact of
diabetes mellitus on percutaneous and surgical treatment of multivessel
coronary disease patients: insights from the Arterial Revascularization
Therapy Study (ARTS) trial. Circulation. 2001;104:533-8.
9. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A,
Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B,
Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary
stenting versus bypass surgery for the treatment of multivessel disease:
the final analysis of the Arterial Revascularization Therapies Study (ARTS)
randomized trial. J Am Coll Cardiol. 2005;46:575-81.
10. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R.
A randomized comparison of a sirolimus-eluting stent with a standard
stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
11. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,
O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS,
Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in
patients with stenosis in a native coronary artery. N Engl J Med.
2003;349:1315-23.
12. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E,
Schampaert E, Breithardt G. Sirolimus-eluting stents for treatment of
patients with long atherosclerotic lesions in small coronary arteries: dou-
ble-blind, randomised controlled trial (E-SIRIUS). Lancet.
2003;362:1093-9.
Clinical research
069_Macaya.qxd  12/04/06  12:39  Page 75
- 76 -
Multivessel revascularization in diabetic patients
13. Serruys PW, Lemos PA, van Hout BA. Sirolimus eluting stent
implantation for patients with multivessel disease: rationale for the Arterial
Revascularisation Therapies Study part II (ARTS-II). Heart. 2004;90:995-8.
14. Serruys PW M, PhD; Ong ATL, MBBS, FRACP; Morice M-C, MD;,
De Bruyne B M, PhD; Colombo A, MD; Macaya C, MD; Richardt G, MD;,
Fajadet J MHC, MD; Dawkins K, MD, FRCP; O’Malley AJ, PhD;, Bressers
M MDD, MD. Arterial Revascularisation Therapies Study Part II -Sirolimus-
eluting stents for the treatment of patients with multivessel de novocoro-
nary artery lesions. EuroIntervention. 2005;I:147-156.
15. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ.
Abciximab reduces mortality in diabetics following percutaneous coronary
intervention. J Am Coll Cardiol. 2000;35:922-8.
16. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C,
Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P,
Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic
patients with non-ST-segment-elevation acute coronary syndromes.
Circulation. 2001;104:2767-71.
17. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N,
Bollwein H, Pache J, Dirschinger J, Berger PP, Schomig A. Randomized
clinical trial of abciximab in diabetic patients undergoing elective percuta-
neous coronary interventions after treatment with a high loading dose of
clopidogrel. Circulation. 2004;110:3627-35.
18. Collaborative meta-analysis of randomised trials of antiplatelet ther-
apy for prevention of death, myocardial infarction, and stroke in high risk
patients. BMJ. 2002;324:71-86.
19. Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M,
Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of
sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS
(SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment
of patients with de novo coronary artery lesions) substudy. Circulation.
2004;109:2273-8.
20. Finn AV, Palacios IF, Kastrati A, Gold HK. Drug-eluting stents for dia-
betes mellitus: a rush to judgment? J Am Coll Cardiol. 2005;45:479-83.
21. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N,
Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-eluting or
sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J
Med. 2005;353:663-70.
22. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA,
Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J,
Moreno R, Fernandez C, Fernandez-Aviles F, Macaya C. Randomized
comparison of sirolimus-eluting stent versus standard stent for percuta-
neous coronary revascularization in diabetic patients: the diabetes and
sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175-83.
23. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R,
Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB. The influ-
ence of diabetes mellitus on acute and late clinical outcomes following
coronary stent implantation. J Am Coll Cardiol. 1998;32:584-9.
24. Ferguson TB, Jr., Hammill BG, Peterson ED, DeLong ER, Grover FL.
A decade of change—risk profiles and outcomes for isolated coronary
artery bypass grafting procedures, 1990-1999: a report from the STS
National Database Committee and the Duke Clinical Research Institute.
Society of Thoracic Surgeons. Ann Thorac Surg. 2002;73:480-9; discus-
sion 489-90.
25. Ghali WA, Quan H, Shrive FM, Hirsch GM. Outcomes after coronary
artery bypass graft surgery in Canada: 1992/93 to 2000/01. Can J Cardiol.
2003;19:774-81.
069_Macaya.qxd  12/04/06  12:39  Page 76
